Breed s Hill Capital LLC Has $1.10 Million Position in Eli Lilly and Company (NYSE:LLY)

Breed s Hill Capital LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 212.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,426 shares of the company's stock after buying an additional 969 shares during the quarter. Eli Lilly and Company accounts for about 0.6% of Breed s Hill Capital LLC's investment portfolio, making the stock its 28th largest position. Breed s Hill Capital LLC's holdings in Eli Lilly and Company were worth $1,101,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in the business. FWG Holdings LLC boosted its stake in Eli Lilly and Company by 0.6% in the 4th quarter. FWG Holdings LLC now owns 2,023 shares of the company's stock worth $1,640,000 after purchasing an additional 12 shares during the period. Morling Financial Advisors LLC boosted its stake in Eli Lilly and Company by 4.7% in the 4th quarter. Morling Financial Advisors LLC now owns 266 shares of the company's stock worth $205,000 after purchasing an additional 12 shares during the period. Garner Asset Management Corp boosted its stake in Eli Lilly and Company by 2.3% in the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after purchasing an additional 12 shares during the period. Platform Technology Partners boosted its stake in Eli Lilly and Company by 0.6% in the 4th quarter. Platform Technology Partners now owns 2,165 shares of the company's stock worth $1,672,000 after purchasing an additional 13 shares during the period. Finally, Argonautica Private Wealth Management Inc. boosted its stake in Eli Lilly and Company by 0.4% in the 4th quarter. Argonautica Private Wealth Management Inc. now owns 3,192 shares of the company's stock worth $2,464,000 after purchasing an additional 13 shares during the period. Institutional investors and hedge funds own 82.53% of the company's stock.

Analysts Set New Price Targets

A number of research firms recently commented on LLY. Truist Financial raised their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Wells Fargo & Company reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. UBS Group decreased their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. HSBC lowered shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their price objective for the stock from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, Cantor Fitzgerald initiated coverage on shares of Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price objective for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating and eighteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $1,011.37.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Down 0.2%

Shares of LLY stock traded down $1.21 on Friday, hitting $713.99. The company's stock had a trading volume of 2,631,160 shares, compared to its average volume of 3,615,016. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The firm's fifty day moving average price is $789.29 and its 200-day moving average price is $803.00. The stock has a market capitalization of $676.67 billion, a price-to-earnings ratio of 60.97, a P/E/G ratio of 1.40 and a beta of 0.48.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. During the same period in the previous year, the firm posted $2.58 EPS. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. Research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be issued a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.84%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.